Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
Read More
Category: Cardiometabolic
EMA Links Semaglutide to Rare Vision Loss Risk
Two-fold increased risk prompts label updates for blockbuster GLP-1 drugs.
Read MoreJ&J Faces $442M Treble Damages Over Catheter Monopoly
J&J’s $147M antitrust penalty tripled to $442M for monopolizing cardiac catheter market.
Read More